Patient and Physician Satisfaction with Rofecoxib in Osteoarthritis: Results of the EVA (Experience with VIOXX in Arthritis) Survey

This publication has 15 references indexed in Scilit:

• Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
  New England Journal of Medicine, 2000
• A Randomized Trial of the Efficacy and Tolerability of the COX-2 Inhibitor Rofecoxib vs Ibuprofen in Patients With Osteoarthritis
  Archives of internal medicine (1960), 2000
• Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip
  Arthritis & Rheumatism, 2000
• Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
  JAMA, 1999
• Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and active-comparator-controlled clinical trial
  Clinical Therapeutics, 1999
• Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial
  Obstetrics & Gynecology, 1999
• Selective cyclooxygenase-2 inhibitors for the treatment of arthritis
  Clinical Therapeutics, 1999
• Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trial
  Clinical Therapeutics, 1999
• Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs
  New England Journal of Medicine, 1999
• Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
  Clinical Pharmacology & Therapeutics, 1999